Combining poly(ADP)-ribose polymerase inhibitors with abiraterone in castration-resistant prostate cancer: Is biomarker testing necessary? Editorial

  

Authors:	Antonarakis, E. S.; Abida, W.
Title:	Combining poly(ADP)-ribose polymerase inhibitors with abiraterone in castration-resistant prostate cancer: Is biomarker testing necessary?
Keywords:	cancer survival; gene mutation; overall survival; cancer combination chemotherapy; monotherapy; cancer patient; biomarkers; biological marker; progression free survival; editorial; tumor marker; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; olaparib; castration resistant prostate cancer; abiraterone; ribose; niraparib; humans; human; male; prostatic neoplasms, castration-resistant; poly(adp-ribose) polymerase inhibitors
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	18
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-20
Start Page:	3291
End Page:	3294
Language:	English
DOI:	10.1200/jco.23.00270
PUBMED:	36952642
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85163673948&doi=10.1200%2fJCO.23.00270&partnerID=40&md5=ee9e41b64603f2a5516c61192af4196f
Notes:	Editorial -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208073